Vigonvita Life Sciences (Vigonvita) has issued a circular convening its 2026 annual general meeting (AGM) for 26 June 2026 in Suzhou. Fifteen resolutions will be put to vote, spanning financial reporting, governance changes, capital mandates and auditor appointment.
Financials and profit distribution • 2025 results and final accounts are up for approval; the board proposes no dividend as it recorded no distributable profit at 31 December 2025.
Board and governance restructuring • Shareholders will elect a six-member second-session board for a three-year term. Executive director nominees are Chairman/CEO Dr Tian Guanghui and Deputy GM Dr Hu Tianwen; Mr Liu Haoxuan stands for non-executive director; independent non-executive candidates are Dr Ju Dianwen, Ms Cao Xinwen and Dr Xu Hongxi. • A special resolution seeks to abolish the Supervisory Committee, transferring its functions to the Board’s Audit Committee, and to amend the Articles of Association accordingly. • Directors’ 2026 remuneration is proposed at RMB100,000 for the non-executive director and RMB200,000 for each independent non-executive director; executive directors receive no additional fee beyond their management salaries.
Subsidiary guarantees • The Company seeks authority to grant joint-liability guarantees of up to RMB50.00 million for credit facilities to wholly-owned units Vigonvita (Lianyungang) Pharmaceutical and Vigonvita (Shanghai) Biopharmaceutical. The mandate runs until the next AGM, with any single guarantee term not exceeding five years.
Auditor rotation • Deloitte will retire at the AGM. The board proposes appointing HLB Hodgson Impey Cheng Limited for the FY2026 audit at an estimated fee of RMB2.48 million.
Capital mandates • General mandate to issue additional H shares, including any sale or transfer of treasury shares, up to 20% of issued H shares (maximum 13.34 million shares based on 66.68 million H shares outstanding as of 3 June 2026). • General mandate to repurchase up to 10% of issued H shares (maximum 6.67 million shares). Repurchased shares may be cancelled or held as treasury stock. • As of 3 June 2026, Vigonvita had 167.60 million shares outstanding, comprising 100.92 million unlisted shares and 66.68 million H shares; the Company held no treasury shares.
Meeting logistics • Shareholders recorded on the H-share register from 23 June to 26 June 2026 (both days inclusive) can attend. Proxy forms must be lodged by 10:00 a.m. on 25 June 2026.
All resolutions, including routine matters such as the 2025 annual report and amendments to procedural rules, will be decided by poll, with cumulative voting applied for director elections.
Comments